Tirzepatide: Tirzepatide is recommended for individuals wishing to manage both Type 2 diabetes and weight loss simultaneously
9:41Staffingly PA Desk Intake queue ready Todays Authorizations Queue MRI Lumbar spine MRICriteria check UHC commercial RX GLP-1 step therapyChart notes requested PROC Cardiac cathPacket complete ready to file INF Biologic infusionBenefit verified J-code confirmed Live submission desk Payer Portals This Morning ePA approvedMRI lumbar UHC portalApproved Portal submission filedCardiac cath AetnaFiled Awaiting determinationBiologic BCBS PPO24 h Reference logged to EHRAuth #PA-48213 postedSynced Approvals & appeals desk Caught Before Denial Todays Progress Authorizations filed18 / 23 Peer-to-peer scheduled3 / 3 Appeal overturnedStep-therapy override approvedWon Peer-to-Peer Coordination When a payer requests a peer-to-peer review, we schedule it and prep the provider with the clinical talking points
Wegovy is a prescription weight loss injection containing semaglutide, part of a group of medications called a GLP-1 (glucagon-like peptide-1)
The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection
While generally consistent with the known class effects of GLP-1 receptor agonists, these side effects may impact long-term adherence and should be carefully considered in clinical decision-making
Other GLP-1 receptor agonists licensed in the UK include dulaglutide (Trulicity), exenatide (Byetta, Bydureon), and lixisenatide (Lyxumia)
